Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes

← catalyst calendar

NCT06033261 · results posted

Sponsored by ModernaTX, Inc. (industry) · MRNA — their whole pipeline →.

Phase
Phase 1/2
Status
Completed
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
303actual
Sites
23
Country
United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis
DateFiledBasisWhat it is
Start2023-09-06actualWhen the study began enrolling
Primary completion2025-04-25actualThe date the last participant is measured for the primary outcome — the readout window
Study completion2025-04-25actualThe whole study's end, after follow-up
First posted2023-09-13actualWhen this record first appeared on the registry
Results posted2026-05-08actualWhen the sponsor posted results to the registry
Record updated2026-05-08actualThe sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

  • Genital Herpes

Interventions

  • Biological: mRNA-1608
  • Biological: BEXSERO

Primary outcomes

what the primary-completion date above is the date OF
Number of Participants With Solicited Local and Systemic ARs
measured Up to Day 64 (Within 7 days after study vaccination)
Number of Participants With Unsolicited Adverse Events (AEs)
measured Up to Day 85 (Up to 28 days after study vaccination)
Number of Participants With Serious Adverse Events (SAEs), Adverse Events of Special Interest (AESIs), and AEs Leading to Study Discontinuation
measured Day 1 through Day 393
Number of Participants With Medically Attended AEs (MAAEs)
measured Day 1 through Day 393

Posted documents

hosted by the registry — we link, never re-serve
Study Protocolposted 2023-08-16 · 1.4 MB · Prot_000.pdf
Statistical Analysis Planposted 2024-09-04 · 2.0 MB · SAP_001.pdf

Permalink · MRNA's whole pipeline · Catalyst calendar · Every registered study · What changed